Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Pharmaceuticals USA Inc.

Latest From Teva Pharmaceuticals USA Inc.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Reimbursement Patents

DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care

Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.

Commercial Digital Health

FTC Sides With Amneal Over Inhaler Patent Dispute With Teva

After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.

Generic Drugs Intellectual Property

Bernie Gets Mostly Pharma-Friendly Drug Pricing Results

Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.

Pricing Debate Politics
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs